In this article, we will be looking at 12 stocks with consistent growth to invest in.

Volatility of the market often decides the nature of stocks preferred by an investor. The current market, fueled by optimism over recent monetary policy decisions, tilts the investment decision in favor of growth stocks. In the run-up to last week’s Federal Reserve meeting, stocks and other assets rallied strongly owing to the conviction that the Federal Open Market Committee would cut its benchmark rate. Major averages consistently climbed, following the quarter-point rate cut. This projected a reignited investor confidence.

The preference is shifting towards growth stocks, as they have consistently demonstrated their performance capabilities in the market over the past few years. CNBC noted the Fed Chair Jerome Powell’s remark that equity prices are fairly highly valued. His statement suggests that valuations are stretched while optimism is driving the market. It, in turn, stresses the importance of selecting stocks that can maintain performance despite the market pressure.

Through the following list, we give you 12 stocks with years of consistent growth that could potentially increase your investment’s resilience and secure its growth in a highly volatile market. Stick with us as we count them down from 12 to 1. The top 5 may already hold a place in your portfolio.

Our Methodology

While compiling our list of 12 stocks with consistent growth to invest in, we followed a few criteria. First, we have included only those stocks with a positive 10-year performance. We filtered mid-cap stocks and above to ensure the companies’ strong financial position. For ranking the stocks, we have used the 10-year performance. All the data used in the article was taken from financial databases and analyst reports, with all information updated as of September 26, 2025.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

12. Strategy Inc (NASDAQ:MSTR)

10-Year Performance: 1351.64%

Strategy Inc (NASDAQ:MSTR) gains a spot in the list of 12 stocks with consistent growth to invest in. Amid a strong second quarter and the acquisition of an additional 1,955 BTC, the company faces rejection of its inclusion in the S&P 500 Index.

Strategy Inc (NASDAQ:MSTR)’s Q2 2025 earnings report, released on July 31, 2025, highlighted a surprising Diluted EPS of $32.52 and Operating Income of $14 billion. The value far surpassed the analyst’s consensus of a -$0.07 loss. During the quarter and into July, the company managed to raise over $10 billion through its ATM programs and IPOs. Additionally, its FY2025 guidance included Operating Income of $34 billion and Diluted EPS of $80.

Later, in September 2025, the company acquired 1,955 additional BTC for $217 million, bringing its total Bitcoin holdings to 638,460 BTC. The move emphasized the company’s dual position as a tech firm and a Bitcoin holder. However, the company was rejected for inclusion in the S&P 500 Index during the September 2025 rebalancing.

Despite the rejection, there is modest bullish activity on the stock. Its growth in the last 10 years has reached over 1351%, signaling the company’s resilience in the U.S. market.

Based in Virginia, Strategy Inc (NASDAQ:MSTR) is an American company founded in 1989. While it continues its original business of providing business intelligence and mobile software, it is now widely known for its corporate strategy of accumulating Bitcoin. Currently, it is one of the largest corporate holders of cryptocurrency.

11. Modine Manufacturing Company (NYSE:MOD)

10-Year Performance: 1497.58%

Modine Manufacturing Company (NYSE:MOD) made it into our list of 12 stocks with consistent growth to invest in. Price target rise and a major sale in the company follow a positive Q1 2026.

On July 31, 2025, Modine Manufacturing Company (NYSE:MOD) reported a 3% year-over-year increase in net sales, reaching $682.8 million and a notable EPS of $1.06, which surpassed the analyst estimates. The company attributed the growth to the increasing demand for its data center cooling solutions, which saw an increase in its sales by 15% from the prior year.

Following these results, the company’s price target was raised among analysts. In August, KeyBanc, while keeping an Overweight rating on the shares, increased the price target from $150 to $160, expressing its confidence in the company’s prospects. Meanwhile, on August 26, 2025, the President of Climate Solutions, Eric S McGinnis, sold 25,932 shares in a transaction worth $3,650,753.

The positive 10-year performance of 1497.58%, however, reflects a solid and durable business in the market for Modine Manufacturing Company (NYSE:MOD).

A global leader in thermal management systems and solutions, Modine Manufacturing Company (NYSE:MOD), was founded in 1916. Headquartered in Wisconsin, the company specializes in designing, engineering, and manufacturing heat transfer products for vehicles (commercial and off-highway), data center cooling, and heating, ventilation, and air conditioning (HVAC) systems.

10. Corcept Therapeutics Incorporated (NASDAQ:CORT)

10-Year Performance: 1534.68%

Corcept Therapeutics Incorporated (NASDAQ:CORT) finds its way into our list of 12 stocks with consistent growth to invest in. Following a strong positive second quarter, the company lowers its full-year guidance and announces the NDA acceptance for a new drug by the FDA.

Corcept Therapeutics Incorporated (NASDAQ:CORT) reported its Q2 2025 earnings on July 31, 2025, in which it highlighted a 45% EPS beat, achieving $0.29 per share against an estimated $0.20. The company’s revenue reached $194.4 million, an 18.7% increase year-over-year. Despite the positive numbers, however, the company reduced its full-year revenue guidance to $850-$900 million.

Additionally, the company announced that the FDA had formally filed a New Drug Application (NDA) for its drug candidate, Relacorilant, as a treatment for platinum-resistant ovarian cancer. The FDA has set a decision date for July 11, 2026. With the filing, the company de-risks a major portion of its pipeline. The company has further stated that it will present new data from the pivotal Phase 3 ROSELLA trial at the European Society for Medical Oncology (ESMO) annual meeting on October 19, 2025.

The 10-year performance of 1534.68%, Corcept Therapeutics Incorporated (NASDAQ:CORT), gains a positive interpretation reflecting a strong foothold in the market.

Corcept Therapeutics Incorporated (NASDAQ:CORT), founded in 1998, is a commercial-stage pharmaceutical company. The California-based company develops drugs, like Korlym, for severe metabolic, psychiatric, and oncologic disorders by modulating the effects of the hormone cortisol.